Drug Markets/Evolocumab

Evolocumab

4 NDCs across 1 manufacturer|0 Generic,4 Brand

Evolocumab is used to treat atherosclerosis and hypercholesterolemia, per the National Library of Medicine's MED-RT classification.

▸ More about this market

In 2024, Medicare Part D spent $2.0 billion on Evolocumab across 2.2 million claims for 460,000 beneficiaries.

Evolocumab is available as 4 NDCs from 1 manufacturer (0 generic, 4 brand), with NADAC prices from $281.81 to $281.97 per MLa 0% difference between cheapest and most expensive. Every pack size and labeler in this drug market is compared side-by-side below.

Total NDCs

4

0G / 4B

Manufacturers

1

competing in market

Price Spread

$281.81 – $281.97

per ML

7d Activity

20 flat

avg -0.0% WoW · of 4 NDCs

Market Price Trend

Monthly average NADAC per unit, split by generic and brand.

Manufacturer Breakdown

1 manufacturer producing EVOLOCUMAB

Drug Portfolio

4 NDCs total, 4 shown

Drug Price 7d Change
REPATHA 140 MG/ML SURECLICK
$281.9692
per ML
-0.01%
REPATHA 140 MG/ML SURECLICK
$281.9692
per ML
-0.01%
REPATHA 140 MG/ML SYRINGE
$281.8058
per ML
0.00%
REPATHA 140 MG/ML SYRINGE
$281.8058
per ML
0.00%

Frequently Asked Questions

What is Evolocumab used to treat?

Evolocumab is used to treat atherosclerosis and hypercholesterolemia, per the National Library of Medicine's MED-RT classification.

How much does Medicare spend on Evolocumab?

In 2024, Medicare Part D spent $2.0 billion on Evolocumab across 2.2 million claims for 460,000 beneficiaries.

How many Evolocumab products are on the market?

The Evolocumab drug market contains 4 NDCs from 1 manufacturer — 0 generic and 4 brand products.

What is the price range for Evolocumab?

NADAC reference prices for Evolocumab range from $281.8058 to $281.9692 per ML — a 0% difference between cheapest and most expensive.

Which manufacturers make Evolocumab?

1 manufacturer lists Evolocumab in NADAC. Ranked by number of NDCs, the largest are Amgen Inc. (4).

How has the price of Evolocumab changed recently?

Over the past 7 days, 0 Evolocumab NDCs rose and 2 fell, with a market-wide average change of -0.0%.